Established in 2019, Shanghai SAFEMED Diagnostics Center is a third-party medical testing institution focusing on precision medicine and in vitro diagnostics. In 2021, SAFEMED won the 'Medical Institution Practice License' and 'Shanghai Pathogenic Microbiology Laboratory Record Certificate' issued by Shanghai. Since its establishment, the company has actively invested in the development of gene detection technology and the construction of related platforms. At present, it has established and improved many products including Hongshi SLAN-96P automatic fluorescent quantitative PCR platform, Illumina NextSeq CN500 next-generation sequencing platform, Snibe MAGLUMIX8 chemiluminescence platform, etc. biological technology platform. It can provide nearly 100 testing items for medical institutions, scientific research institutes and individuals at home and abroad, covering precise sequencing of pathogenic microorganisms, maternal and child health, genetic testing for individualized drug use for tumors, hereditary tumor screening, genetic testing for genetic diseases, and life science research Genetic testing services related to clinical diagnosis and clinical research in a series of fields.
The center is committed to early nucleic acid screening of infectious diseases, especially in the nucleic acid detection of 'hepatitis B virus, hepatitis C virus, human immunodeficiency virus (1+2 type)'. Applied to the screening of blood donation specimens. In the future, it will be more used in the early screening of clinical specimens to reduce the risk of cross-infection in the hospital.
At the same time, the center has established the first dynamic gene bank in the world, has the exclusive patent of dynamic gene sequencing technology, and is the only authorized unit in China for the accurate sequencing of pathogenic microorganisms by Zymo Research Company of the United States. The dynamic gene sequencing adopted by the company can not only qualitatively detect gene mutations, but also quantitatively analyze gene expression. It provides true and reliable technical support for early and early diagnosis of tumors, tumor medication and postoperative follow-up. The core team has worked in the field of international advanced gene sequencing for many years, and has been conducting gene sequencing and analysis in the laboratory of Yale University School of Medicine all year round. .
In the future, SAME Medical will provide a more effective 'production-university-research' platform for domestic diagnostic technologies. This platform will bring together a group of experts in related technical fields, contribute to human health.
